Clover Corp Ltd (ASX: CLV) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Clover Corp Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $167.00 million
P/E Ratio 15.50
Dividend Yield 2.32%
Shares Outstanding 167.00 million
Earnings per share 0.063
Dividend per share 0.03
Year To Date Return 25.63%
Earnings Yield 6.45%
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Clover Corp Ltd (ASX: CLV)
    Latest News

    a woman
    Share Gainers

    Clover share price rockets 19% higher on strong profit growth

    The Clover Corporation Limited (ASX:CLV) share price has been on the move today following the release of the fast-growing company's…

    Read more »

    a woman
    ASX Share Market News

    Is the Bellamy's takeover a signal to invest in infant formula?

    Yesterday, Bellamy’s Australia Ltd (ASX: BAL) received a takeover bid at a price of $13.25 per share. Is now the…

    Read more »

    a woman
    52-Week Highs

    Is it too late to buy these high-flying ASX shares?

    The Magellan Financial Group Ltd (ASX:MFG) share price is one of three trading at a 52-week high. Is it too…

    Read more »

    a woman
    ASX Share Market News

    Can the Clover Corporation share price continue pushing all-time highs?

    The Clover Corporation Limited (ASX: CLV) share price has increased by over 50% since the start of 2019.

    Read more »

    a woman
    ASX Share Market News

    Top brokers name 3 ASX shares to buy next week

    Top brokers have given buy ratings to TPG Telecom Ltd (ASX:TPM) shares and two others…

    Read more »

    a woman
    Share Gainers

    Clover Corporation share price jumps 6% on strong first-half result

    A strong first-half result is sending the Clover Corporation share price higher.

    Read more »

    a woman
    Share Gainers

    The share price of this alternative ASX stock to A2 Milk just surged 6% today

    There are nervous times for shareholders in A2 Milk Company Ltd (ASX: A2M) and Bellamy's Australia Ltd (ASX: BAL), but…

    Read more »

    a woman
    Growth Shares

    Why these 2 small-cap shares have doubled in value in a year

    The ASX Small Ordinaries index has performed strongly over the past 12 months. Here are two small-cap shares that have…

    Read more »

    a woman
    ⏸️ Portfolio Construction

    Are small cap shares the best place to invest?

    Small cap stocks have been losing their gloss recently but some experts believe the sector is well placed to make…

    Read more »

    a woman
    ⏸️ Investing

    These 3 emerging healthcare shares could be the next big thing

    These three emerging healthcare shares are worth keeping your eye on.

    Read more »

    a woman
    ⏸️ Investing

    Is the share price of A2 Milk Company Ltd (ASX: A2M) in a "dead cat bounce"?

    A2 Milk Company Ltd (ASX: A2M) is among the biggest losers on S&P/ASX 200 (Index:^AXJO) (ASX:XJO) this afternoon as investors…

    Read more »

    a woman
    ⏸️ Investing

    Why Bapcor Ltd & Challenger Ltd are among 3 stocks soaring on the S&P/ASX 200 today

    Bapcor Ltd (ASX:BAP) and Challenger Ltd (ASX:CGF) hit the gains today.

    Read more »

    Frequently Asked Questions

    Yes, Clover Corporation has historically paid two fully franked shareholder dividends a year.

    Clover Corporation generally pays its dividends in April and November.

    No, Clover Corporation does not have a dividend reinvestment plan at the current time. 

    Clover Corporation listed on the ASX on 30 November 1999.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    20 Oct 2026 $0.0125 100.00% Final 19 Nov 2026
    15 Apr 2026 $0.0100 100.00% Interim 30 Apr 2026
    20 Oct 2025 $0.0100 100.00% Final 20 Nov 2025
    09 Apr 2025 $0.0075 100.00% Interim 24 Apr 2025
    21 Oct 2024 $0.0075 100.00% Final 18 Nov 2024
    30 Oct 2023 $0.0075 100.00% Final 20 Nov 2023
    05 Apr 2023 $0.0075 100.00% Interim 27 Apr 2023
    25 Oct 2022 $0.0100 100.00% Final 22 Nov 2022
    06 Apr 2022 $0.0050 100.00% Interim 28 Apr 2022
    25 Oct 2021 $0.0050 100.00% Final 16 Nov 2021
    07 Apr 2021 $0.0050 100.00% Interim 29 Apr 2021
    27 Oct 2020 $0.0250 100.00% Final 18 Nov 2020
    29 Oct 2019 $0.0175 100.00% Final 20 Nov 2019
    08 Apr 2019 $0.0063 100.00% Interim 30 Apr 2019
    29 Oct 2018 $0.0125 100.00% Final 20 Nov 2018
    09 Apr 2018 $0.0050 100.00% Interim 01 May 2018
    27 Oct 2017 $0.0000 100.00% Final 20 Nov 2017
    10 Apr 2017 $0.0025 100.00% Interim 01 May 2017
    27 Oct 2016 $0.0050 100.00% Final 21 Nov 2016
    11 Apr 2016 $0.0025 100.00% Interim 02 May 2016
    29 Nov 2010 $0.0125 100.00% Final 15 Dec 2010

    CLV ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Clover Corp Ltd

    Clover Corporation Limited (ASX: CLV) provides nutritional ingredients, particularly omega-3 and omega-6 fatty acids. The company is involved in the production of encapsulated powders, and research and product development of infant nutrition and functional food ingredients.

    Clover Corporation offers Nu-MegaHi tuna oils for use in infant formula and pharmaceutical products, as well as Ocean Gold refined tuna oils. Its products include DHA oils, DHA powders, and other nutritional oils drawn from patented microencapsulation technologies. Geographically, the group has a business presence in Australia, New Zealand, Asia, Europe, and the Americas. The majority of the company's revenue is derived from the Asian market. 

    CLV Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    04 Nov 2026 $1.00 $0.03 3.09% 1,956,251 $0.97 $1.00 $0.96
    03 Nov 2026 $0.97 $0.00 0.00% 71,620 $0.97 $0.99 $0.96
    02 Nov 2026 $0.97 $-0.03 -3.00% 303,192 $0.98 $1.04 $0.97
    30 Oct 2026 $1.00 $0.01 1.01% 101,159 $1.00 $1.00 $0.98
    29 Oct 2026 $1.00 $-0.01 -1.00% 162,102 $1.00 $1.00 $0.98
    28 Oct 2026 $1.00 $0.00 0.00% 728,933 $1.01 $1.01 $1.00
    27 Oct 2026 $1.01 $0.02 2.03% 285,326 $1.00 $1.01 $1.00
    26 Oct 2026 $0.99 $-0.03 -2.96% 431,332 $1.03 $1.03 $0.98
    23 Oct 2026 $1.02 $-0.01 -0.98% 251,217 $1.02 $1.05 $0.99
    22 Oct 2026 $1.02 $0.00 0.00% 112,483 $1.03 $1.03 $0.99
    21 Oct 2026 $1.03 $-0.03 -2.86% 138,833 $1.05 $1.05 $1.02
    20 Oct 2026 $1.05 $0.02 1.94% 143,580 $1.00 $1.05 $1.00
    19 Oct 2026 $1.03 $0.01 0.98% 149,397 $1.01 $1.05 $1.01
    16 Oct 2026 $1.03 $-0.01 -0.97% 1,294,147 $1.03 $1.05 $1.02
    15 Oct 2026 $1.03 $0.00 0.00% 313,774 $1.03 $1.03 $1.00
    14 Oct 2026 $1.03 $0.01 0.98% 534,550 $1.03 $1.04 $1.03
    13 Oct 2026 $1.02 $0.01 0.99% 102,405 $1.01 $1.02 $1.01
    12 Oct 2026 $1.01 $0.01 1.00% 83,270 $1.01 $1.01 $0.99
    09 Oct 2026 $1.00 $-0.02 -1.96% 10,451 $1.02 $1.02 $1.00
    08 Oct 2026 $1.02 $-0.01 -0.97% 54,652 $1.03 $1.03 $0.98
    07 Oct 2026 $1.03 $0.08 8.42% 78,367 $0.95 $1.03 $0.95
    06 Oct 2026 $0.95 $-0.05 -5.03% 50,000 $1.00 $1.00 $0.95

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    28 Oct 2026 Simon Green Buy 10,000 $10,273
    On-market trade.
    27 Oct 2026 Brett Hewlett Buy 10,000 $10,005
    On-market trade.
    20 Oct 2026 Ian Glasson Buy 50,000 $51,500
    On-market trade.
    09 Oct 2026 Andrew Allibon Buy 5,000 $5,016
    On-market trade.
    08 Oct 2026 Fiona Pearse Buy 30,827 $30,049
    On-market trade.
    08 Oct 2026 Andrew Allibon Buy 22,553 $22,553
    On-market trade.
    06 Oct 2026 Fiona Pearse Buy 10,000 $10,013
    On-market trade.
    18 Nov 2025 Peter Davey Buy 529,638 $368,098
    On-market trade. 16,16,905 Performance Rights
    18 Nov 2025 Peter Davey Sell 255,199 $177,363
    On-market trade. 1,361,706 Performance Rights

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Ian David Glasson Non-Executive Director Feb 2017
    Mr Glasson is former CEO of PGG Wrightson based in Christchurch, New Zealand. He was formerly CEO of Gold Coin Group / Zuellig Agriculture which managed a portfolio of animal feed operations and farming ventures throughout South-East Asia. Prior to that he was CEO for seven years of Sucrogen which generated revenues of nearly $2 billion and had contacts across the local and international food and beverage sector and retail market. He has also had agribusiness experience with Goodman Fielder and Gresham Rabo, as well as spending the first sixteen years of his career in the oil and gas sector with Esso. He is the Chair of the People & Culture Committee and a Member of the Risk Committee.
    Ms Toni Brendish Non-Executive Director Oct 2020
    Ms Brendish has more than 30 years of experience working in blue chip FMCG, healthcare, manufacturing, agriculture, and telecommunication companies in Asia, Australia, and New Zealand, including over 20 years in Chief Executive Officer / Managing Director roles. Toni's last executive role was as Chief Executive Officer of Westland Milk Products in the South Island of New Zealand. Prior to this, Toni spent 11 years working for the Danone Group as Managing Director of their Infant Formula and Dairy businesses in Australia, New Zealand, Malaysia and Indonesia. She has also worked for Kimberly-Clark and Colgate Palmolive, together with several other blue chip FMCG organizations. She is a member of the Risk, People &
    Culture Committees.
    Mr Rupert Anthony Harrington Non-Executive DirectorNon-Executive Chairman Jul 2015
    Mr Harrington is an experienced company Director with over 30 years of experience as a Non-Executive Director of companies operating in manufacturing, industrial services, health and technology. He has been involved in private equity since 1987 and is one of the founders of the Australian industry
    Mr Peter J Davey Chief Executive OfficerManaging Director Dec 2014
    Mr Davey has a record of building businesses across a range of industry sectors. He has held senior management positions within several manufacturing and distribution companies. Mr Davey was formerly Executive Manager AgriProducts and a director of Viterra Australia Limited, responsible for the AgriProducts division that traded in agricultural inputs, fertilizer, seed and wool. In earlier roles, Mr Davey headed the Sales and Marketing divisions of FMP Products and Hi Fert Pty Ltd. During his career, Mr Davey has had a particular focus on marketing-based businesses operating in the Asia and Oceania regions.
    Mr Brett Hewlett Non-Executive Director Oct 2026
    Mr Hewlett is a non-executive director who has commercial and engineering expertise having worked internationally with Alfa Laval and Tetra_Pak for 17 years. Most recently Brett was Chairman of Comvita (2020 - 2024), and previously CEO for 10 years. Brett has held non-executive director roles in New Zealand with Comvita (NZX:CVT), Quayside Holdings, Bluelab Inc (board Chair), SeaDragon (NZX:SEA) and in the USA with Derma Sciences Inc (Nasdaq:DSCI).
    Dr Simon Green Non-Executive Director Oct 2020
    Mr Green has years of experience in the biotechnology industry focused on the discovery, development and commercialization of life-saving medicines. He was actively involved in CSL's global expansion over a 17-year period and held roles as Senior Vice President, Global Plasma R&D and General Manager of CSL's manufacturing plants in Germany and Australia. Simon is the founder and CEO of Immunosis Pty Ltd, a startup diagnostics Company. He is the Chair of the Innovation & Development
    Committee and a Member of the Risk, People & Culture Committee.
    Ms Fiona Pearse Non-Executive Director Aug 2025
    Ms Pearse is an experienced Non-Executive Director who has commercial expertise obtained from a commercial, finance and tax career during almost two decades at complex listed, global companies. Fiona is the current Chair of the Board of U Ethical, one of Australia's ethical Fund Managers. She is also a Non-Executive Director of Monash Health. She is Chair of the Risk Committee and a Member of the People & Culture Committee.
    Mr Andrew Allibon Chief Financial OfficerCompany Secretary May 2021
    -
    Andrew Allibon Chief Financial OfficerCompany Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Citicorp Nominees Pty Limited 29,204,408 17.49%
    HSBC Custody Nominees (Australia) Limited 21,558,135 12.91%
    UBS Nominees Pty Ltd 11,726,358 7.02%
    Anacacia Pty Ltd <Wattle Fund A/C> 9,452,458 5.66%
    Evelin Investments Pty Limited 7,550,000 4.52%
    J P Morgan Nominees Australia Pty Limited 7,278,245 4.36%
    Jeremy And Lynette King Superannuation Pty Ltd 6,000,000 3.59%
    Thorney International Pty Ltd 3,967,539 2.38%
    King Equity Capital Pty Ltd 2,361,000 1.41%
    Incani & Papadopoulos Super Pty Ltd 2,010,000 1.20%
    Sandhurst Trustees Ltd <Millex Ethical Fund A/C> 2,000,000 1.20%
    Mr Sundeep Kalra & Mr Anoop Kalra & Mrs Shikha Mohanty <Ganesh Super Fund A/C> 1,747,825 1.05%
    BNP Paribas Noms (Nz) Ltd 1,549,382 0.93%
    Alex King Family Holdings Pty Ltd <Alex King Family A/C> 1,500,000 0.90%
    Cpu Share Plans Pty Ltd <Clv Eip Unallocated A/C> 1,393,457 0.83%
    Dmx Capital Partners Ltd 1,393,345 0.83%
    Jiva Holdings Pty Ltd <Kalra Family A/C> 1,217,500 0.73%
    Ray & Dawn Pty Ltd <King Super Fund A/C> 1,135,367 0.68%
    Mr Garrie Ellice 960,000 0.57%
    Mrs Malaine Christine Haet 944,800 0.57%

    Profile

    since

    Note